BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
BioMarin Pharma (BMRN) Tops Q1 EPS by 19c, Offers FY Guidance
April 29, 2021 4:13 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.09, $0.19 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $486 million versus the consensus estimate of $446.45 million.
GUIDANCE:
BioMarin Pharma sees FY2021 revenue of $1.75-1.85 billion, versus the consensus of... More
